vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Sanofi (SNY). Click either name above to swap in a different company.
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of th...
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | — | ||
| Q3 25 | $9.0M | — | ||
| Q2 25 | $17.1M | — | ||
| Q1 25 | $4.2M | — | ||
| Q4 24 | $5.0M | — | ||
| Q3 24 | $6.5M | — | ||
| Q2 24 | $7.3M | — | ||
| Q1 24 | $10.0M | — |
| Q4 25 | $-8.9M | — | ||
| Q3 25 | $-57.1M | — | ||
| Q2 25 | $-34.7M | — | ||
| Q1 25 | $-45.6M | — | ||
| Q4 24 | $-34.2M | — | ||
| Q3 24 | $-51.1M | — | ||
| Q2 24 | $-36.9M | — | ||
| Q1 24 | $-40.6M | — |
| Q4 25 | -63.7% | — | ||
| Q3 25 | -851.8% | — | ||
| Q2 25 | -290.2% | — | ||
| Q1 25 | -1479.6% | — | ||
| Q4 24 | -1441.0% | — | ||
| Q3 24 | -1439.4% | — | ||
| Q2 24 | -1276.2% | — | ||
| Q1 24 | -551.5% | — |
| Q4 25 | -19.9% | — | ||
| Q3 25 | -637.8% | — | ||
| Q2 25 | -203.3% | — | ||
| Q1 25 | -1077.2% | — | ||
| Q4 24 | -677.6% | — | ||
| Q3 24 | -785.4% | — | ||
| Q2 24 | -504.3% | — | ||
| Q1 24 | -408.0% | — |
| Q4 25 | $-0.03 | — | ||
| Q3 25 | $-0.19 | — | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | $-0.11 | — | ||
| Q3 24 | $-0.17 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.14 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
